This study is designed to evaluate the **long-term safety** of a medication called **KarXT** in people with **psychosis,** which is a mental health problem that affects how the brain processes information. This psychosis is associated with **Alzheimer's Disease (AD)**, a condition affecting memory and thinking skills. The study is an **Open-Label Extension (OLE)**, meaning that all participants will know they are taking KarXT, and it will last for **52 weeks** (about a year). To join, participants must have completed one of three previous studies labeled **CN012-0026, CN012-0027, or CN012-0056**. They must also be between **55 and 90 years old** and have a caregiver who spends at least **10 hours a week** with them. Participants must not have any serious medical conditions that could interfere with the study. - **Study Duration:** 52 weeks. - **Eligibility:** Previously completed certain studies; aged 55-90. - **Commitment:** Must have a caregiver for support. This study helps researchers understand if KarXT is safe for long-term use in people with Alzheimer's-related psychosis.